BRAF V600E

12 registered clinical trials studyying BRAF V600E — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsa NCT07506109	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Recruiting	Preoperative Hemogram Parameters and BRAF Molecular Test Detected by Bethesda 3 Cytology. NCT06539702	Saglik Bilimleri Universitesi	—
Completed	Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma NCT05304546	Dr. Ronnie Shapira	Phase 2
Recruiting	Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies NCT05786924	Institut de Recherches Internationales Servier	Phase 1 / Phase 2
Completed	Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorec NCT05510895	AIO-Studien-gGmbH	Phase 2
Completed	A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fl NCT05004350	Pierre Fabre Medicament	Phase 2
Active Not Recruiting	ENCOrafenib With Binimetinib in bRAF NSCLC NCT04526782	Intergroupe Francophone de Cancerologie Thoracique	Phase 2
Terminated	A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib. NCT04534283	Anita Turk	Phase 2
Terminated	Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG NCT03973918	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 2
Unknown	Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation NCT03543306	Asan Medical Center	Phase 2
Terminated	A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas NCT03593993	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	—
Recruiting	Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy NCT03042221	University of Colorado, Denver	—